Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
IPO Year: 2016
Exchange: NASDAQ
Website: clearsidebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/21/2024 | $6.00 | Buy | Chardan Capital Markets |
| 6/25/2024 | $5.00 | Outperform | Oppenheimer |
| 3/11/2022 | $11.00 → $10.00 | Market Outperform | JMP Securities |
| 12/15/2021 | $19.00 → $9.00 | Outperform | Wedbush |
| 7/29/2021 | $10.00 | Buy | HC Wainwright & Co. |
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter. Information about the Company's quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company's website. About Clearside Biomedical, Inc. Clearsid
ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025, at 1:00 p.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months. About Clearside Biomedical, Inc. Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the d
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 12:45 p.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of
- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China - - Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside's SCS Microinjector® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 27, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector® Provides Targeted and Compartmentalized Delivery of Therapeutics Directly to the Retina - ALPHARETTA, Ga., March 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that six abstracts related to the Company's suprachoroidal drug delivery platform have been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Meetin
- Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention-Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development - - Unique Ability to Re-Dose CLS-AX vs Rescue Supports Regulatory & Commercial Strategy - ALPHARETTA, Ga., March 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that presentations on the Company's lead clinical program, CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD), and its suprachoroi
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call ca
- CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development - ALPHARETTA, Ga., March 06, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the receipt of the formal meeting minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) relating to CLS-AX (axitinib injectable suspe
ALPHARETTA, Ga., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that two subgroup analyses were presented from the ODYSSEY Phase 2b clinical trial at the Angiogenesis, Exudation, and Degeneration 2025 meeting. ODYSSEY was a randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week trial evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related macular degeneration (wet AMD). The presentation, entitled "Phase 2b CLS-AX OD
ALPHARETTA, Ga., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development, will participate in a Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference on Tuesday, February 11, 2025, at 9:20 a.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentation
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
3/A - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form
Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
DEFA14A - Clearside Biomedical, Inc. (0001539029) (Filer)
DEF 14A - Clearside Biomedical, Inc. (0001539029) (Filer)
PRE 14A - Clearside Biomedical, Inc. (0001539029) (Filer)
10-K - Clearside Biomedical, Inc. (0001539029) (Filer)
8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
SCHEDULE 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
10-Q - Clearside Biomedical, Inc. (0001539029) (Filer)
8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13D/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
Chardan Capital Markets initiated coverage of Clearside Biomedical with a rating of Buy and set a new price target of $6.00
Oppenheimer initiated coverage of Clearside Biomedical with a rating of Outperform and set a new price target of $5.00
JMP Securities reiterated coverage of Clearside Biomedical with a rating of Market Outperform and set a new price target of $10.00 from $11.00 previously
Wedbush resumed coverage of Clearside Biomedical with a rating of Outperform and set a new price target of $9.00 from $19.00 previously
HC Wainwright & Co. initiated coverage of Clearside Biomedical with a rating of Buy and set a new price target of $10.00
Wedbush reiterated coverage of Clearside Biomedical with a rating of Outperform and set a new price target of $18.00 from $6.00 previously
JMP Securities reiterated coverage of Clearside Biomedical with a rating of Market Outperform and set a new price target of $9.00 from $8.00 previously
Wedbush resumed coverage of Clearside Biomedical with a rating of Buy and set a new price target of $6.00
Wedbush resumed coverage of Clearside Biomedical with a rating of Buy and set a new price target of $5.00
ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside's Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board. George Lasezkay, PharmD, JD, President and Chief Executive Officer, Clearside Biomedical, commented, "Tony is a highly respected member of our Board, bringing a wealth of strategic leadership experie
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs. "We are privileged to welcome Dr. Yiu to our SAB, given his leadership in the research and adoption of new delivery approaches for t
ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. "We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space," said Clay Thorp, Chair of the Clearside Board of Directors. "We believe Tony's significant experience driving value for biotech companies through successful pipeline development, financing, partnerin
ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024. Dr. Chong is a board-certified retinal specialist with more than 25 years of experience as a retinal physician and navigating all phases of ophthalmic drug development. George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, "Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically foc
ALPHARETTA, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced the appointment of Arshad M. Khanani, M.D., M.A, F.A.S.R.S and Lejla Vajzovic, M.D., F.A.S.R.S to its Scientific Advisory Board (SAB). Clearside's SAB is comprised of industry leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs. The SAB members are: Thomas A. Ciulla, M.D., M.B.A., ChairDavid S. Boyer, M.D.David M. Brown, M.D.Arshad M. Khanani, M.D., M.A., F.A.S.R.S
ALPHARETTA, Ga., June 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced the appointment of Susan L. Coultas, Ph.D., as Chief Clinical Officer. In this role, Dr. Coultas serves as a member of the executive team and has overall responsibility for planning the initiation and execution of Clearside's clinical trials, including oversight of all clinical development operations. "We are very excited to have Susan join our team," said George Lasezkay, Pharm.D., J.D., Clearside's President and Chief Executive Officer. "With her b
ALPHARETTA, Ga., March 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Benjamin R. Yerxa, Ph.D., has been appointed to the Company's Board of Directors, effective March 2, 2022. Dr. Yerxa currently serves as Chief Executive Officer of the Foundation Fighting Blindness, the world's leading private funding source for retinal degenerative disease research. "As we continue to expand Clearside's pipeline based on our proprietary SCS injection platform, we are pleased to add Dr. Yerxa, who brings deep scientific, ophtha
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter. Information about the Company's quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company's website. About Clearside Biomedical, Inc. Clearsid
- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China - - Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside's SCS Microinjector® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 27, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call ca
- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a Differentiated Flexible Dosing Approach Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) - - Recent Commercial Licensing Agreement for China by a Global Ophthalmic Pharmaceutical Company Provides Strategic Validation of Clearside's Suprachoroidal Platform - - Compelling Data Presentations at AAO Demonstrated Potential Safety and Efficacy Benefits of Suprachoroidal Delivery Using Clearside's Proprietary SCS Microinjector® in Multiple Clinical Programs - - M
ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (877) 545-0523 (
- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did Not Require Any Additional Treatment up to 6 Months - - Reduced Treatment Burden by 84% Over 6 Months - - Webcast and Conference Call Today at 8:00 A.M. ET with Management and Key Opinion Leader and Board-Certified Retinal Specialist, Roger Goldberg, M.D., MBA - ALPHARETTA, Ga., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed - - Recent Key Opinion Leader Webinar Highlighted the Broad Applicability and Real-World Experience of Suprachoroidal Drug Delivery - ALPHARETTA, Ga., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our P
ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets. In lieu of a second quarter 2024 conference call, the Company hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on Wednesday, July 24, 2024. The replay of this event is available on the Clearside website under the Investors section: Events and Presentations. Quarterly earnings conference calls are expected to
ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-645-4404 (U.S.) or
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-50